Updating its recommendations, the U.S. Preventive Services Task Force (USPSTF) recommend that women have breast cancer mammography screenings every two years between ages 50 to 74. In 2002, the USPSTF recommended that women have mammograms every one to two years at age 40. Now they warn that the risks of mammography may outweigh the benefit for many women. Women ages 40 to 49 at high risk for breast cancer should talk to their physicians about...Read More
Cancer
Subscribe to this Category
Updating its recommendations, the U.S. Preventive Services Task Force (USPSTF) recommend that women have breast cancer mammography screenings every two years between ages 50 to 74. In 2002, the USPSTF recommended that women have mammograms every one to two years at age 40. Now they warn that the risks of mammography may outweigh the benefit for many women. Women ages 40 to 49 at high risk for breast cancer should talk to their physicians about...Read More
Inflammatory bowel disease (IBD) refers to both ulcerative colitis and Crohn's disease. These diseases cause chronic inflammation and weakness of the gastrointestinal tract. IBD is different than irritable bowel syndrome (IBS), which does not involve intestinal inflammation or damage. Now research reports that skin cancer may be linked to medications used to treat IBD. The study, presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego, investigated the association of IBD...Read More
On November 5, 2009 the American Institute for Cancer Research (AICR) held a news conference at the Annual Research Conference on Food, Nutrition, Physical Activity and Cancer in Washington, DC. AICR researchers presented new estimates linking obesity to higher cancer risk and lower cancer survival. According to the AICR report, obesity causes over 100,000 cancer cases yearly in the U.S. The report combined the latest US cancer incidence data with conclusions of the recent American...Read More
Previous studies suggest that soy isoflavone genistein intake is associated with a lower risk of prostate cancer. Genistein has been shown to block cell metastasis of human prostate cancer cells in mice. Now for the first time, research reports the discovery of genistein's target in preventing the spread of prostate cancer. The study, published in the Journal of the National Cancer Institute, investigated the target for genistein in prostate cancer cells. Researchers at Northwestern University...Read More
Research suggests that infection and inflammation may increase the risk of prostate cancer. Gammaretroviruses have been found to cause cancer in animal cells. Now research reports that the XMRV (xenotropic murine leukemia virus-related virus) retrovirus was discovered in human prostate cancer cells. This finding can aid the development of prostate cancer diagnostic tests, antiviral treatments and viral prevention. The study, published in Proceedings of the National Academy of Sciences, investigated the association of XMRV with prostate...Read More
Although overall cancer rates are falling, thyroid cancer incidence has been rising. For the past three decades, studies have shown that thyroid cancer rates are increasing about 6% a year. More aggressive screening may be one explanation for the rise. Now research conducted at the American Cancer Society reports that the rise may be due to other factors including radiation exposure, obesity and diet. The study, published in the journal Cancer, evaluated thyroid cancer incidence between...Read More
The American Cancer Society estimates that about 1.4 million Americans will be diagnosed with cancer in 2006. Many cancer patients experience nausea and vomiting associated with chemotherapy. The marijuana drug Cesamet treats nausea and vomiting associated with chemotherapy in cancer patients who don't effectively respond to conventional anti-nausea treatments. In 1985 the FDA first approved Cesamet, made by Eli Lilly and Company, but the drug was discontinued in 1989. Valeant Pharmaceuticals International bought Cesamet from...Read More
A large clinical trial sponsored by the National Cancer Institute will tell whether women with breast cancer will benefit from chemotherapy prior to initiating the grueling series of treatments. The study, referred to as TAILORx (Trial Assigning Individualized Options for Treatment), will enroll 10,000 women with breast cancer at more than 900 institutions across the United States and Canada. OncotypeDXTM (a diagnostic test developed by Genomic Health, Inc., in Redwood, Calif., in collaboration with the...Read More
